Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial.

MLA

Blauvelt, Andrew, et al. “Abrocitinib Induction, Randomized Withdrawal, and Retreatment in Patients with Moderate-to-Severe Atopic Dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN Phase 3 Trial.” Journal of the American Academy of Dermatology, vol. 86, no. 1, Jan. 2022, pp. 104–12. EBSCOhost, https://doi.org/10.1016/j.jaad.2021.05.075.

APA

Blauvelt, A., Silverberg, J. I., Lynde, C. W., Bieber, T., Eisman, S., Zdybski, J., Gubelin, W., Simpson, E. L., Valenzuela, F., Criado, P. R., Lebwohl, M. G., Feeney, C., Khan, T., Biswas, P., DiBonaventura, M., Valdez, H., Cameron, M. C., & Rojo, R. (2022). Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial. Journal of the American Academy of Dermatology, 86(1), 104–112. https://doi.org/10.1016/j.jaad.2021.05.075

Chicago

Blauvelt, Andrew, Jonathan I. Silverberg, Charles W. Lynde, Thomas Bieber, Samantha Eisman, Jacek Zdybski, Walter Gubelin, et al. 2022. “Abrocitinib Induction, Randomized Withdrawal, and Retreatment in Patients with Moderate-to-Severe Atopic Dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN Phase 3 Trial.” Journal of the American Academy of Dermatology 86 (1): 104–12. doi:10.1016/j.jaad.2021.05.075.